J
Jay Mei
Researcher at Celgene
Publications - 21
Citations - 1159
Jay Mei is an academic researcher from Celgene. The author has contributed to research in topics: Lenalidomide & Population. The author has an hindex of 13, co-authored 20 publications receiving 1081 citations.
Papers
More filters
Journal ArticleDOI
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Antonio Palumbo,Roman Hájek,Michel Delforge,Martin Kropff,Maria Teresa Petrucci,John Catalano,Heinz Gisslinger,Wieslaw Wiktor-Jedrzejczak,Mamia Zodelava,Katya C Weisel,Nicola Cascavilla,Genadi Iosava,Michele Cavo,Janusz Kloczko,Joan Bladé,Meral Beksac,Ivan Spicka,Torben Plesner,Joergen Radke,Christian Langer,Dina Ben Yehuda,Alessandro Corso,Lindsay Herbein,Zhinuan Yu,Jay Mei,Christian Jacques,Meletios A. Dimopoulos +26 more
TL;DR: MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age.
Journal ArticleDOI
Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown,Wael A. Harb,Brian T. Hill,Janice Gabrilove,Jeff P. Sharman,Marshall T. Schreeder,Paul M. Barr,James M. Foran,Thomas P. Miller,Jan A. Burger,Kevin R. Kelly,Daruka Mahadevan,Shuo Ma,Yan Li,Daniel W. Pierce,Evelyn Barnett,Jeffrey Marine,Monika Miranda,Ada Azaryan,Xujie Yu,Pilar Nava-Parada,Jay Mei,Thomas J. Kipps +22 more
TL;DR: Clinical studies have shown that Bruton’s tyrosine kinase (BTK) inhibitors are well tolerated, with promising clinical activity.
Journal ArticleDOI
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
Meletios A. Dimopoulos,Michel Delforge,Roman Hájek,Martin Kropff,Maria Teresa Petrucci,Philip Lewis,Annabel Nixon,Jingshan Zhang,Jay Mei,Antonio Palumbo +9 more
TL;DR: The MM-015 trial as mentioned in this paper assessed the effect of lenalidomide-based therapy on health-related quality of life (QoL) in patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma
Antonio Palumbo,Meletios A. Dimopoulos,Michel Delforge,Martin Kropff,Robin Foà,Zhinuan Yu,Lindsay Herbein,Jay Mei,Christian Jacques,John Catalano +9 more
TL;DR: PFS was significantly improved in patients who received MPR followed by lenalidomide maintenance compared with those who received MP followed by placebo maintenance, demonstrating a highly statistically significant improvement in PFS for patients treated with MPR compared with MP as first-line treatment for MM patients.
Journal ArticleDOI
Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown,Wael A. Harb,Brian T. Hill,Janice Gabrilove,Jeff P. Sharman,Marshall T. Schreeder,Paul M. Barr,James M. Foran,Thomas P. Miller,Jan A. Burger,Kevin R. Kelly,Daruka Mahadevan,Shuo Ma,Evelyn Barnett,Jeffrey Marine,Pilar Nava-Parada,Ada Azaryan,Jay Mei,Thomas J. Kipps +18 more
TL;DR: This phase 1 trial investigated the safety, dose limiting toxicities (DLT), and clinical activity of CC-292 monotherapy in subjects with relapsed or refractory (R/R) CLL or non-Hodgkin9s lymphoma.